Corrections
Communicating emerging risks of SGLT2 inhibitors—timeliness and transparency of medicine regulators
BMJ 2020; 369 doi: https://doi.org/10.1136/bmj.m1745 (Published 04 May 2020) Cite this as: BMJ 2020;369:m1745
In this analysis (BMJ 2020;369:m1107, doi:10.1136/bmj.m1107, published 29 April 2020), one of the five serious risks of SGLT2 inhibitors was omitted—acute kidney injury. The full list is diabetic ketoacidosis, lower limb amputation, severe genitourinary infections, acute kidney injury, and fracture. This has been amended online.